Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-b (Q60228496)
Jump to navigation
Jump to search
scientific article published on 01 August 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-b |
scientific article published on 01 August 2009 |
Statements
Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis (English)
Ingrid Strusberg
Patrick Durez
Melvin Churchill
Won Park
Bernardo Antonio Pons-Estel
Sudha Visvanathan
Weichun Xu
Roy M Fleischmann
Larry W Moreland
Elizabeth C Hsia
Eric Jason B Amante
Mittie K Doyle
Mahboob U Rahman